Fabry and Cardiomyopathy (FaCard) Epidemiological Study for the Analysis of Biomarkers and the Clinical Course of Patients With Fabry Disease and the N215S-mutation "FaCard"
Recruiting
Phase N/A Results N/ASummary of Purpose
Primary objective and endpoint is the analysis of the long-term course of lyso-Gb3 and its clinical correlation to the progression of the cardiomyopathy in N215S-Fabry patients.
Read More →Trial Milestones
The following dates are available for this trial. Trial information last updated on 12 June 2017.
1 Aug 2011 | 6 Sep 2011 | 1 Aug 2019 | 1 Sep 2019 | 1 Jun 2017 | Unavailable |
Start Date | First Received | 1st Completion | Completion | Verification | Results |
---|
Trial Basics
Conditions
Sponsors
Trial Design
- Observation: Cohort
- Perspective: Prospective
- Sampling: Probability Sample
Contacts
- Arndt Rolfs, MD
- Sabine Roesner
sabine.roesner@med.uni-rostock.de 49-381-494
View Trial Locations
Recruitment
- Enrollment: 40
- Gender: All
- Minimum Age: 18 Years
- Accepts Healthy Volunteers: No
- 1 location, 1 country
Principal Investigator
- Arndt Rolfs, MD
University of Rostock, Albrecht-Kossel-Institute for Neuroregeneration